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Abstract
 
Loss of function of the guanine nucleotide binding protein RhoA blocks pre-T cell differentia-
tion and survival indicating that this GTPase is a critical signaling molecule during early thy-
mocyte development. Previous work has shown that the Rho family GTPase Rac-1 can ini-
tiate changes in actin dynamics necessary and sufficient for pre-T cell development. The
present data now show that Rac-1 actions in pre-T cells require Rho function but that RhoA
cannot substitute for Rac-1 and induce the actin cytoskeletal changes necessary for pre-T cell
development. Activation of Rho is thus not sufficient to induce pre-T cell differentiation or
survival in the absence of the pre-T cell receptor (TCR). The failure of RhoA activation to
impact on pre-TCR–mediated signaling was in marked contrast to its actions on T cell re-
sponses mediated by the mature TCR 
 
 
 
/
 
  
 
complex. Cells expressing active RhoA were thus
hyperresponsive in the context of TCR-induced proliferation in vitro and in vivo showed aug-
mented positive selection of thymocytes expressing defined TCR complexes. This reveals that
RhoA function is not only important for pre-T cells but also plays a role in determining the
fate of mature T cells.
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Introduction
 
The development and maturation of T lymphocytes in the
thymus is an essential process for the formation of the pe-
ripheral immune system and is also an exceedingly valuable
model for probing the physiological role of signal transduc-
tion molecules in vivo. Thymocyte development involves
an ordered sequence of differentiation and proliferation.
Early thymocyte progenitors, which lack expression of
the major histocompatibility receptors CD4 and CD8
(CD4
 
 
 
CD8
 
 
 
, double negatives [DNs]
 
*
 
), initiate rearrange-
ments of the TCR-
 
 
 
 locus and, if successful, this allows
surface expression of a functional pre-TCR complex (1, 2).
The pre-TCR instructs cells to proliferate rapidly and to
undergo further differentiation to express CD4 and CD8.
CD4
 
 
 
CD8
 
 
 
 double positive (DP) thymocytes rearrange
their TCR-
 
 
 
 locus, express a mature TCR 
 
 
 
/
 
  
 
complex,
and are subjected to the processes of positive and negative
selection that generate CD4
 
 
 
 and CD8
 
 
 
 single positive
(SP) thymocytes (3, 4).
There has been considerable interest in the signal trans-
duction molecules that mediate antigen receptor signaling
in pre-T cells and for thymocyte selection. In particular,
Rho family guanine nucleotide binding proteins/GTPases
appear to regulate these critical decision points in thy-
mocyte development. This was first noted in mice lacking
Vav-1, a guanine nucleotide exchange factor (GEF) with
selectivity for Racs (5). Vav-1 loss in lymphocytes causes
defects in activation-dependent actin polymerization (6, 7)
and a block in pre-T cell differentiation and positive and
negative selection (8–10). The action of Vav-1 on the ac-
tin cytoskeleton reflects the GEF actions of Vav-1 on
Rac-1, a GTPase which selectively organizes filamentous
actin structures. The developmental defects caused by loss
of Vav-1 in pre-T cells can thus be corrected by expres-
sion of an activated mutant of Rac-1 which modulates ac-
tin dynamics (11). In this context, activation of Rac-1 po-
tentiates pre-T cell differentiation and proliferation and is
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able to substitute for the pre-TCR complex to initiate T
cell differentiation into DPs in recombinase activating
gene (Rag)-1 null mice that lack expression of the pre-
TCR (11).
The function of a second GTPase Rho is also required
for thymocyte development at the pre-T cell stage (12–
15). In cell lines, in vitro RhoA can regulate actin cytoskel-
etal structure, gene transcription, and cell transformation
(for a review, see reference 16). However the ability of
Rho to control specific cell fate development in vivo has
only been explored in the context of thymocyte develop-
ment. Thus loss of Rho function blocks pre-T cell differ-
entiation and proliferation (13, 14). Rho function is also
absolutely necessary for survival of signaling pathways in
early thymocyte progenitors (13, 15). The signal transduc-
tion pathways used by the pre-TCR to control T cell pro-
liferation and differentiation involve protein tyrosine ki-
nases (17, 18), and Rho has been shown to act downstream
of the Src kinase p56lck and to be required for activated
p56lck mutants to drive pre-T cell differentiation (19).
Rho is also a critical component of the signaling pathways
used to suppress the proapoptotic p53 checkpoint during
thymocyte development (15).
Despite the overwhelming evidence that Rho function
is essential for thymocyte development, it is not known if
Rho signaling is sufficient for thymocyte survival, differ-
entiation, and proliferation. One way to probe Rho func-
tion further is to examine the effects of gain of function
mutants of Rho in the thymus. There have been several
studies probing the consequences of expressing active
RhoA mutants in leukemic T cell lines. This approach has
indicated a role for RhoA in the modulation of T cell po-
larization and migration (20), in the regulation of T cell
spreading after TCR engagement (21), as well as in the
potentiation of the transcriptional activity of AP-1 during
T cell activation (22). The relevance of these observations
to the in vitro role of RhoA in the thymus is not known
and results obtained in studies of transformed cell lines
must always be subjected to the proviso that they may not
mimic what happens under physiological conditions. Ac-
cordingly, the objective of this study was to study the
consequences of RhoA activation in primary thymocytes
and peripheral T lymphocytes. The human CD2 pro-
moter and locus control region (CD2-LCR) was used to
express an active mutant of RhoA, V14RhoA in normal
T cells of transgenic mice. Analysis of these mice showed
that RhoA activation is sufficient to stimulate integrin-
mediated cell adhesion in thymocytes but is not sufficient
for pre-T cell survival, differentiation, and proliferation. It
was also seen that RhoA can strikingly potentiate TCR-
 
 
 
/
 
 
 
–mediated responses in primary lymphocytes both in
vitro and in vivo, a previously unrecognized function for
this GTPase. This study also reveals crosstalk between the
GTPases Rac-1 and Rho in thymocyte development. Ac-
tivation of Rac-1 is sufficient to induce pre-T cell differ-
entiation whereas RhoA activation is not. Nevertheless,
the actions of Rac-1 in the thymus are dependent on Rho
signaling.
 
Materials and Methods
 
Transgenic Mice.
 
A 0.7-kb cDNA fragment comprising myc
epitope-tagged sequences of V14RhoA was cloned in the Sma I
site of a transgenic expression vector containing the promoter,
the first intron and the LCR of the human CD2 gene (23). The
resulting plasmid was cut with restriction enzymes at a KpnI–
NotI site to generate 12-kb fragments comprising the promoter
and intron sequences and the LCR driving the expression of
V14RhoA. These fragments were used to generate transgenic
mouse lines following standard protocols. Transgene-carrying
mice were identified by PCR of genomic DNA purified from
mouse ear punches. The primers used were Vah1 (5
 
 
 
-GGTG-
CAGTCTCCAAAGAATTC-3
 
 
 
) and U46 (5
 
 
 
-CCGAAGATC-
CTTCTTATTCCCAAC-3
 
 
 
) or Vah4 (5
 
 
 
-GGGGACAAT-
GAGTTTTCTGCTG-3
 
 
 
) and RO1 (5
 
 
 
-GTGGGACACAGC-
TGGGCAGG-3
 
 
 
). Stable V14RhoA transgenic lines were estab-
lished by backcrossing transgene carrying founder mice with
C57/BL6/J mice. L61 Rac-1 and CD2 C3 transgenic mice, and
Vav-1
 
 
 
/
 
 
 
 and Rag-1
 
 
 
/
 
  
 
mice have been described in detail else-
where (10, 11, 14, 24). Mice were bred and maintained under
specific pathogen free conditions in the Imperial Cancer Re-
search Fund Biological Resources Unit.
 
Cell Preparation.
 
Thymi were obtained by dissection from
6–9-wk-old mice. Tissue was disaggregated by mincing with fine
forceps and forced through a fine mesh filter to obtain a single
cell suspension. Total cell numbers were determined by micro-
scopic observation of Trypan’s blue–stained cells using a Neu-
bauer hemocytometer.
 
Western Blot Analysis.
 
Freshly prepared thymocytes were
washed twice in ice-cold PBS and subjected to lysis using buffer,
20 mM Tris, pH 7.5, 10% glycerol, 1% NP40, 150 mM NaCl,
10 mM MgCl
 
2
 
, 1 mM sodium orthovanadate, 1 mg/ml aproti-
nin, 1 mg/ml leupeptin, 1 mg/ml chemostatin, and 1 mM
PMSF. The extract was centrifuged at 15,000 
 
g
 
 for 15 min at
4
 
 
 
C. Proteins were concentrated by precipitation with 1.5 vol of
acetone. Proteins corresponding to 10
 
7
 
 cells were separated in
15% SDS-PAGE, transferred to polyvinylidene difluoride mem-
branes and detected by Western blot analysis using specific anti-
RhoA (26C4) monoclonal antibody (Santa Cruz Biotechnol-
ogy) and enhanced chemiluminescence (Amersham Pharmacia
Biotech).
 
Flow Cytometric Analysis.
 
Antibodies (BD PharMingen) were
obtained conjugated to either FITC, PE, allophycocyanin, or bi-
otin. Biotinylated antibodies were revealed using streptavidin-
Tricolor (Caltag). Thymocytes and splenocytes were stained for
surface expression of the following markers using the antibodies
given in parenthesis: CD8 (53-5.8); CD4 (RM4-5); CD25 (IL-
2R 
 
 
 
-chain, 3C7); CD3
 
 
 
 (145-2C11); TCR-
 
 
 
 (
 
 
 
-chain, H57-
597); B220 (CD45R, RA3-6B2); CD44 (Pgp-1, IM7); Thy 1.2
(CD90.2, 30-H12); pan NK DX5; Mac-1 (CD11b, M1/70);
Gr-1 (Ly-6G, RB6-8C5); HY-TCR (T3-.70); Vb11-TCR
(RR3.15); and V
 
 
 
8–TCR (F23.1). Cells were stained with satu-
rating concentrations of antibody at 4
 
 
 
C for 30 min at 10
 
6
 
 cells
per sample, in a 96-well V-bottomed shaped microtiter well plate
in 100 
 
 
 
l of PBS containing 1% BSA. Cells were washed with
this buffer in between incubations and before analysis on a calibur
fluorescence-activated cell sorter (FACS
 
®
 
; Becton Dickinson).
Events were collected and stored ungated in list mode using
CELLQuest™ software. Live cells were gated according to their
forward-scatter and side-scatter profiles and data were analyzed
using CELLQuest™ software.
 
Proliferation Assays.
 
Freshly isolated thymocytes from normal
littermate control (NLC) and V14RhoA mice were seeded in 
905
 
Corre et al.
triplicates at 10
 
6 
 
cells per milliliter in 96 well flat-bottomed mi-
crotitre plates (Nunc) in 200 
 
 
 
l of medium RPMI, 10% FCS,
and 50 
 
 
 
M 2-
 
 
 
 mercaptoethanol. Cells were either left unstimu-
lated or stimulated for 48 h with indicated concentrations of anti-
CD3 mAb (145.2C11, coated on plate overnight at 4
 
 
 
C), or with
phorbol-12,13 dibutyrate (PdBu) and calcium ionophore iono-
mycine (Calbiochem) at indicated concentrations. Cells were
then labeled with 1 
 
 
 
Ci of [
 
3
 
H]thymidine (Amersham Pharmacia
Biotech), incubated for further 12–18 h, and harvested on filters.
Incorporated radioactivity was quantified using a microplate scin-
tillation counter.
 
Carboxyfluorescein Diacetate Succinimidyl Ester Labeling.
 
Freshly
isolated thymocytes were resuspended at a concentration of 10
 
7
 
cells per milliliter in RPMI 1640 and labeled with 5 
 
 
 
M car-
boxyfluorescein diacetate succinimidyl ester (CFSE; Molecular
Probes) by incubation for 5 min at 37
 
 
 
C. After incubation, excess
CFSE was quenched by adding excess amounts of FCS and wash-
ing in RPMI 1640. For CFSE analysis of cell division, CFSE-
labeled thymocytes were seeded in 24-well plates (2 
 
 
 
 10
 
6
 
 cells
per well in RPMI 1640 containing 10% FCS) either uncoated or
precoated with anti-CD3 antibody. Cells in uncoated wells were
either left untreated or stimulated with Pdbu and ionomycin at
the concentrations indicated. After culturing for 48 h, cells were
collected and analyzed by flow cytometry for CD4 and CD8
staining and CFSE fluorescence.
 
Cell Attachment Assays.
 
Flat-bottomed Maxisorp 96-well
plates (Nunc) were left uncoated as controls or precoated with
different concentrations of mouse fibronectin (Chemicon) in PBS
overnight at 4
 
 
 
C. Wells were washed twice with PBS, and non-
specific binding sites were blocked with 1% denatured BSA for
1 h at 37
 
 
 
C. Freshly isolated thymocytes were washed in RPMI
and labeled with 2.5 mM BCECF-AM (Calbiochem) in the same
medium for 30 min at 37
 
 
 
C, followed by one further wash. La-
beled thymocytes were resuspended in RPMI and added to fi-
bronectin precoated plates (10
 
6
 
 cells per well in 100 ml of me-
dium). Plates were centrifuged at 40 
 
g 
 
for 1 min and subsequently
incubated for 30 min at 37
 
 
 
C. Nonadherent cells were removed
by washing three times in warm RPMI medium. Adhesion was
quantified by recording emission at 530 nm, after excitation at
485 nm, using Fluoroscan II (Labsystems, Inc.). Specific adhesion
is obtained by subtracting background adhesion (mean reading for
wells uncoated with fibronectin) from the reading for each well.
This specific adhesion is expressed as a percentage of the total
emission before the incubation, i.e., percentage of total cell input
adhering to the well.
 
Microscopy.
 
Freshly isolated thymocytes were plated on 24-
well plates (2 
 
 
 
 10
 
6
 
 cells per well in RPMI 1640) containing 1-cm
glass coverslips precoated with either fibronectin at 50 mg/ml
or poly-L-lysine (Sigma-Aldrich). After incubation for 1 h at
37
 
 
 
C nonattached cells were removed, the coverslips were
washed twice with RPMI 1640, and attached cells were fixed
with 4% paraformaldehyde in PBS by incubation for 15 min at
room temperature. After fixation, coverslips were washed three
times with PBS and mounted upside down to a glass slide using
Gelvatol (Monsanto Chemicals). Phase contrast images were ob-
tained with a Zeiss Laser Scanning Microscope LSM 510 with a
63
 
 
 
 NA/1.4 planapochromat oil immersion lens (Nikon).
 
Intracellular Calcium Analysis.
 
Thymocytes were incubated
Indo-1 acetoxy-methyl ester (1 mM indo-1; Calbiochem) for 45
min at 37
 
 
 
C in RPMI 1640, 10% FCS, washed, and stained with
anti-CD8 tricolor, anti-CD4-PE, and anti-CD3 (145-2C11).
Four-color flow cytometric analysis was performed on a BD
LSR flow cytometer (Becton Dickinson). Tricolor and PE were
excited by an argon laser (488 nM, 20 mW) and Indo-1 by a UV
helium/cadmium laser (325 nM, 8 mW). Indo-1 emission was
detected using 424/440 nm (violet) and 510 (blue) bandpass fil-
ters. To determine the relative intracellular calcium concentra-
tion, cells were warmed to 37
 
 
 
C, analyzed for 1 min to establish
baseline calcium levels, and CD3 was crosslinked by the addition
of the indicated concentrations of goat anti–hamster IgG (Jackson
ImmunoResearch Laboratories). Acquisition was continued in
real time for up to 8 min.
 
Results
 
Thymocyte Development in Transgenic Mice Expressing Con-
stitutively Active V14RhoA.
 
The human CD2-LCR (23)
was used to express a constitutively active mutant of Rho,
V14RhoA, in T cells of transgenic mice (Fig. 1 A).
V14RhoA expression was determined by immunoblotting
of thymocyte lysates with RhoA mAb. V14RhoA is myc
epitope-tagged and has reduced migration in SDS-PAGE
and can be clearly distinguished from endogenous RhoA.
Two V14RhoA transgene-carrying founder lines were es-
tablished that showed similar levels of V14RhoA expres-
sion in the thymus (Fig. 1 B) and similar phenotypes. Thy-
mocyte numbers in V14RhoA thymi were normal (Fig. 1
C) and all major subsets of CD4CD8 DNs, DPs, and SPs
were present (Fig. 1 D). There is a huge body of work
showing that RhoA regulates changes in the actin cytoskel-
eton in epithelial cells and fibroblasts (16). The actin cy-
toskeleton has an important role in regulating cell adhesion.
Accordingly, we examined the effect of V14RhoA in thy-
mocyte adhesion; it has been reported RhoA can regulate
cell adhesion in lymphocytes (25). Thymocytes express the
integrin 
 
 
 
4
 
 
 
1 which acts as the main receptor for the ex-
tracellular matrix protein fibronectin in these cells (26, 27).
We analyzed the attachment of thymocytes from normal
and V14RhoA mice to plate-bound mouse fibronectin.
The data in Fig. 2 A show that thymocytes expressing ac-
tive RhoA have higher levels of adhesion to fibronectin
than normal thymocytes. The gross morphology of thy-
mocytes expressing V14Rho was indistinguishable from
normal adhesive cells (Fig. 2 B).
 
Characterization of the Effects of Active Rho on TCR-
 
 
 
 Selec-
tion.
 
A main objective of this study was to examine the
effects of Rho activation in pre-T cells because it is known
that Rho signals are essential for this stage of thymocyte
differentiation (13, 14). CD4
 
 
 
CD8
 
 
 
 DN cells can be sub-
divided according to two different cell surface markers:
CD25 and CD44. The first T cell progenitors are
CD44
 
 
 
CD25
 
 
 
 (DN1), followed by the CD44
 
 
 
CD25
 
 
 
(DN2) stage where TCR-
 
 
 
 rearrangements initiate. 
 
 
 
 re-
arrangements are completed in CD44
 
 
 
CD25
 
 
 
 (DN3) cells
and, if successful, allow expression of functional pre-TCR
complexes which instruct cells to proliferate rapidly, down-
regulate CD25, upregulate CD2 and CD5, and differenti-
ate into CD44
 
 
 
CD25
 
 
 
 DN4 cells and then to progress to
the DP stage. The data in Fig. 3 show CD25 and CD44
staining profiles of DN thymocytes and reveal that
V14RhoA thymi have a normal distribution of DN3 and 
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DN4 cells (Fig. 3 A) and express normal levels of CD2, a
marker of pre-TCR function (data not shown). Thus, by
these criteria, activation of RhoA has no discernible impact
on pre-T cell biology.
To probe the actions of RhoA in more detail, we exam-
ined the effects of RhoA activation on thymocyte develop-
ment in a model of defective pre-T cell differentiation,
namely Rag-1 null mice. These mice are defective in anti-
Figure 1. Thymic pheno-
type of CD2-V14RhoA trans-
genic mice. (A) Diagram of the
CD2-V14RhoA construct. A
0.7-kb fragment containing
human V14RhoA myc-tagged
cDNA was subcloned at Sma I
site in the human CD2 vector.
Position of hCD2 promoter and
LCR are shown. Arrows indi-
cate the position of transgene-
specific primer pairs used in
PCR-based screening for trans-
gene-carrying mice. (B) Thy-
mic expression of V14RhoA transgene. Proteins of thymocytes lysates from NLC mice and transgenic mice (V14RhoA) (106 cells) were separated on a
15% SDS-PAGE. Detection of endogenous RhoA and transgene V14RhoA was performed by Western blot analysis using a specific monoclonal anti-
RhoA antibody. Results are shown for the two different transgenic lines generated (2029.1 and 2036.F). Top arrowhead, myc-tagged transgenic
V14RhoA; bottom arrowhead, endogenous RhoA. (C) Absolute thymocyte number in CD2-V14RhoA mice. Thymocyte cell numbers from 6–8-
wk-old NLC (n   8) and V14RhoA are shown (n   10). (D) CD4/CD8 profiles on V14RhoA thymocytes. Thymocytes from NLC and V14RhoA
mice were isolated, stained with anti-CD4-PE and anti-CD8-FITC, and analyzed by flow cytometry. Two dimensional dot plots representative of five
independent experiments are shown.
Figure 2. Adhesion to fibronectin is enhanced in thymocytes expressing constitutively active RhoA. (A) Thymocyte adhesion to fibronectin. Cell ad-
hesion of freshly isolated thymocytes to increasing concentrations of mouse fibronectin was assayed as described in Materials and Methods. Specific adhe-
sion is expressed as the percentage of attached cells for NLC (black) and CD2 V14RhoA (white) thymocytes. Data represent means   SD of triplicates.
One experiment representative of three is shown. (B) Cell morphology of thymocytes attached to fibronectin. Freshly isolated thymocytes were attached
to fibronectin or poly-L-lysin coated coverslips and analyzed by light microscopy as described previously. Panels show phase contrast images of thymocytes
from nontransgenic mice (a and c) or V14RhoA transgenic mice (b and d), attached to fibronectin (a and b) or poly-L-lysin (c and d). Bar, 10  m. 
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gen receptor gene rearrangements and show a block in thy-
mocyte development at the CD4CD8 DN stage because of
failed pre-TCR expression (24). It is possible to overcome
the lack of pre-TCR in Rag-1
 
 
 
/
 
  
 
mice by expression of
gain of function mutants of the Rho family GTPase Rac-1
(11). This GTPase mimics the signaling function of the
pre-TCR and induces CD4CD8 DP differentiation when
expressed in Rag-1
 
 
 
/
 
 
 
 pre-T cells (11). To determine
whether expression of active RhoA could induce T cell
development in the absence of the pre-TCR complex,
V14RhoA transgenic mice were crossed with Rag-1
 
 
 
/
 
 
 
mice. V14RhoA/Rag-1
 
 
 
/
 
  
 
thymi were then examined for
the presence of the various thymocyte subsets (Fig. 3 B). In
Rag-1
 
 
 
/
 
  
 
mice, thymocyte development is blocked at
DN3 stage and CD4
 
 
 
CD8
 
 
 
 cells are not generated. Ex-
pression of active RhoA does not change this phenotype
(Fig. 3 B). Thymocyte cellularity was low in Rag-1
 
 
 
/
 
 
 
mice and was not rescued by expression of active RhoA.
 
Activation of RhoA Potentiates TCR-
 
   
 
–induced Prolifera-
tive Responses In Vitro and In Vivo.
 
TCR levels of DPs
were normal in V14RhoA transgenic mice but it was ob-
served reproducibly that SPs that developed in these mice
had lower levels of TCR complexes (Fig. 4 A). Therefore,
we examined the responsiveness of these cells to activation
via the TCR complex with anti-CD3 antibodies. Accord-
ingly, the proliferative responses of thymocytes to plated
CD3 antibodies were monitored. Interestingly, despite the
lower levels of the TCR complexes on SPs from
V14RhoA mice, these cells were hyperresponsive to plated
CD3 antibodies for the induction of proliferation (Fig. 4
B). There was no detectable difference in the response of
the cells to activation with the pharmacological reagents
calcium ionophore and phorbol ester (Fig. 4 B), demon-
strating the specificity of hyperresponsiveness of these cells
to TCR/CD3 triggering.
The fluorescent cell permeable dye CFSE can be used to
monitor cell division. The data in Fig. 4 C show the CFSE
staining profiles of T cells from normal and V14RhoA
thymi both before and after activation. Unstimulated NLC
and V14RhoA T cells show a single peak of CFSE staining
whereas cells activated with CD3 antibodies or calcium
ionophore and phorbol esters show multiple peaks of CFSE
staining. A higher percentage of V14RhoA T cells (82%)
committed to proliferate compared with the NLCs (52%).
Moreover, more of the V14RhoA cells had undergone
multiple divisions when compared with control cells. In
contrast, there was no difference in the CFSE staining pro-
files of T cells activated with ionomycin and Pdbu.
To probe the mechanisms of RhoA effects on T cells
we looked at immediate biochemical responses triggered
by the TCR. Ligation of antigen receptors activates cellu-
lar tyrosine kinases that, via a network of adapters and en-
zymes, regulate intracellular calcium. The calcium re-
sponses of V14RhoA T cells triggered by CD3 antibodies
were indistinguishable from normal cells. The ability of
V14RhoA to potentiate T cell responses thus occurs at a
Figure 3. Effect of activated RhoA on pre-T cell differ-
entiation. (A) Analysis of CD4 8  DN populations in
V14RhoA transgenic mice. Thymocytes from V14RhoA
and NLC mice were analyzed for expression of CD25 and
CD44 by lineage exclusion of all CD4 and CD8 DP and
SP as well as cells of non-T cell lineage using a panel of bi-
otinylated antibodies to CD4, CD8, CD3, B220, Mac-1,
NK,   , and Gr-1, revealed with streptavidin allophycocy-
anin, and costained with anti-CD44 CyChrome, anti-
CD25 FITC, and Thy-1.2 PE. Dot plots show CD44/
CD25 profiles in lineage-, Thy-1.2  gated cells. Number
indicates percentage of total DN thymocytes. (B) Activated
RhoA does not restore CD4 CD8  DP differentiation
in Rag-1 /  mice. Thymocytes from Rag-1 /   and
V14RhoA/Rag-1 /  were stained for CD25 and CD44
(left panel) as described in A, for CD4 and CD8 (right
panel) and analyzed by flow cytometry. Dot plots show
CD44/CD25 profiles in Lineage-, Thy-1.2  cells (left) and
CD4/CD8 profiles in Thy-1.2  cells (right). Results are
representative of at least three independent experiments.908 In Vivo Analysis of RhoA Function
point distal to the immediate biochemistry triggered by
antigen receptors.
Activation of RhoA Potentiates TCR- / –induced Pro-
liferative Responses In Vivo. In vitro proliferation experi-
ments suggested that activation of RhoA could potentiate
responses mediated by the mature TCR-   . More-
over, we had also noted that RhoA activation was asso-
ciated with increased integrin-mediated cell adhesion
and it has been proposed that cosignaling by integrins
would facilitate TCR-mediated responses within the
thymus (28). To examine the effect of RhoA signaling
on TCR- / –mediated responses in the thymus, we ex-
amined the effect of V14RhoA on positive and negative
selection of thymocytes expressing TCR transgenes. The
HY T cell receptor is specific for the male HY antigen
presented by MHC class I H-2 Db molecules (29). Thy-
mocytes expressing the HY-specific TCR are negatively
selected in male 2Db mice and undergo massive deletion
resulting in very few detectable DP and SP with a strong
reduction in overall thymic cellularity. The expression of
active RhoA did not change this phenotype (data not
shown).
Figure 4. Mature thymocytes expressing constitutively active RhoA are hyperresponsive to TCR/CD3 triggering. (A) Analysis of CD3/TCR expres-
sion on thymic populations. Thymocytes from NLC and V14RhoA mice were stained for CD4, CD8, and CD3 . Histograms show expression of CD3
on CD4 CD8  DP population, CD4  single positive (CD4 SP), and CD8  single positive (CD8 SP). Mean fluorescence intensity for CD3 expression
is shown in the histograms. (B) TCR-stimulated in vitro proliferation of thymocytes. Total thymocytes from NLC and V14RhoA transgenic mice were
prepared as described previously. Proliferation of thymic T cells in response to a range of concentrations of plate-bound anti-CD3 antibody, or a combi-
nation of PdBu (5 ng/ml) and ionomycin (0.5 ng/ml), was assessed by the incorporation of [3H]thymidine during the last 12 h of a 36-h assay. Graph
shows mean of [3H]thymidine incorporation (  SEM) of triplicate samples. Circles represent proliferation of thymocytes to PdBu plus ionomycin. The
experiment shown is representative of three different experiments. White circles, NLC; black circles, V14RhoA. (C) CFSE analysis of cell division in
TCR-stimulated CD4 SP thymocytes. CFSE-labeled thymocytes from NLC and V14RhoA transgenic mice were stimulated with soluble anti-CD3 an-
tibodies or PdBu (5 ng/ml) and ionomycin (0.5 ng/ml) as described previously. After 48 h in culture cells were stained for CD4 and CD8 and analyzed
by flow cytometry for CD4 and CD8 expression and CFSE fluorescence. Histograms show CFSE fluorescence gated on CD4 SP cells of NLC (shaded)
or V14RhoA (open) mice. (D) TCR-stimulated intracellular calcium flux in CD4 SP thymocytes. Thymocytes were preloaded with Indo-1 coated with
anti-CD3 antibodies and stained for CD4 and CD8. Intracellular calcium flux upon CD3 triggering was analyzed by flow cytometry as described in Ma-
terials and Methods. Cells were stimulated with goat anti–hamster, to crosslink the anti-CD3, at the concentrations and times indicated. Panels show in-
tracellular calcium concentration in CD4 SP thymocytes as a ratio of Indo-1 violet/blue fluorescence versus time. Each channel on the time axis repre-
sents 500 msec.909 Corre et al.
Thymocytes from female HY-TCR transgenic mice are
positively selected on a H-2 Db background and develop
into mature CD8 SP cells. Strikingly, the thymic pheno-
type of V14RhoA/HY-TCR female double transgenic
mice was markedly different from the normal phenotype
seen in HY-TCR transgenic females. The data in Fig. 5 A
(top) show that, in thymocytes from female mice that co-
express the HY-TCR and V14RhoA, there are markedly
increased numbers of positively selected HY-TCR trans-
genic T cells. This was also seen in analysis of splenic popu-
lations (Fig. 5 A, bottom). To examine further the effects
of RhoA on thymocyte selection, V14RhoA transgenic
mice were bred with a different TCR transgenic line, F5-
TCR transgenic mice. The F5 transgenic TCR recognizes
an influenza nuclear protein peptide in the context of
H-2Db (30) and thymocytes are positively selected to CD8
SP cells in mice with an H-2Db background. The results in
Fig. 5 B show that, in thymocytes and spleens coexpressing
the F5-TCR transgene and V14 Rho, there are increased
numbers of F5-TCR transgenic T cells. The analyses of the
V14RhoA/HY-TCR and V14RhoA/F5-TCR double
transgenic mice reveals that positive selection is more effi-
cient in thymocytes expressing active RhoA.
Crosstalk between the GTPases Rac-1 and RhoA in Thy-
mocyte Development. The inability of active RhoA to res-
cue pre-T cell differentiation in Rag-1 /   mice is in
marked contrast to the actions of a closely related GTPase
Rac-1 (11). Rac-1 is activated by the guanine nucleotide
Figure 5. Activated RhoA enhances positive selection.
(A) Analysis of thymic and splenic CD4/CD8 populations
in female HY-TCR/V14RhoA double transgenic mice.
Thymocytes and splenocytes of HY-TCR and HY-
TCR/V14RhoA female mice were stained for CD4,
CD8, and HY-TCR and analyzed by flow cytometry.
Panels show CD4/CD8 profile gated on HY-TCRhigh
thymocytes (top) and splenocytes (bottom). Absolute
numbers (106 cells) of CD8 SP thymocytes and spleno-
cytes expressing high levels of HY-TCR are indicated.
(B) Analysis of thymic and splenic CD4/CD8 populations
in F5-TCR/V14RhoA double transgenic mice. Thy-
mocytes and splenocytes of F5-TCR and F5-TCR/
V14RhoA mice were stained for CD4, CD8, and V 11
and analyzed by flow cytometry. Panels show CD4/CD8
profile gated on V 11high thymocytes and splenocytes.
Absolute numbers (106 cells) of CD8 SP thymocytes and
splenocytes expressing high levels of V 11 are indicated.
Each two dimensional dot plot shown is representative of
at least three independent experiments.910 In Vivo Analysis of RhoA Function
exchange protein Vav-1 (5) and mice lacking this protein
have shown thymic hypocellularity associated with a pre-
TCR block and inefficient negative and positive selection
(9, 10). The developmental defects caused by loss of Vav-1
in pre-T cells can be corrected by expression of a constitu-
tively active mutant of Rac-1 that regulates the actin cyto-
skeleton (11). In this context, V14RhoA and active Rac-1
have some common effects on actin dynamics (20, 31) and
Vav-1 and Rac-1 are both able to induce RhoA-mediated
changes in the actin cytoskeleton in in vitro models (31,
32). To explore physiologically relevant links between
Rac-1 and RhoA in the thymus we examined the Rho de-
pendency of Rac-1–induced pre-T cell differentiation and
compared the ability of RhoA and Rac-1 to rescue T cell
development in Vav-1 null mice.
To examine the Rho dependency of Rac-1–induced
pre-T cell differentiation, CD2L61 Rac-1 transgenic mice
expressing constitutively active Rac-1 were bred to mice in
which the CD2-LCR was used to give pre-T cell expres-
sion of Clostridium botulinum C3 transferase, a selective in-
hibitor of Rho (14). In CD2-C3 transgenic mice, pre-T
cell receptor expression occurs normally but further devel-
opment is blocked at the DN3 cell stage. Thymi from
CD2-C3 mice look like Rag /  thymi in that they show a
DN block at the DN3 stage and they fail to generate
CD4CD8 DPs (14). Activation of Rac-1 can induce thy-
mocyes to differentiate from CD4CD8 DNs to CD4CD8
DPs in Rag /  thymocytes that lack a pre-TCR complex.
The data in Fig. 6 A show that Rac-1 cannot induce
CD4CD8 DPs in the absence of Rho function. Rac-1 also
potentiates DN3/DN4 transition (11) as revealed by
CD44/25 staining profiles of Rac-1 DNs; all cells in the
DN3 gate have lower levels of CD25 than normal and are
shifted into a population intermediate between the DN3
and DN4 stage. The ability of active Rac-1 to modulate
DN3/DN4 transition is lost in CD2-C3 transgenic mice
(Fig. 6 B). Thus the actions of Rac-1 in pre-T cells are de-
pendent on functional Rho signaling pathways.
Pre-T cell developmental defects in Vav-1 null mice can
be rescued by expression of an activated mutant of Rac-1,
L61Rac-1. Therefore, we determined if expression of
V14RhoA could reverse the pre-T cell developmental de-
fects caused by loss of Vav-1. Analysis of V14RhoA/Vav-
1 /  mice showed that expression of the active RhoA mu-
tant did not reconstitute cellularity in Vav-1 /  thymi (Fig.
7 A). Moreover, CD44/CD25 analysis revealed that
V14RhoA/Vav-1 /  mice continue to be blocked at the
DN3 stage of pre-T cell development and show a skewed
accumulation of DNs and depleted DPs (Fig. 7 B and C).
Defective antigen receptor signal transduction in Vav-1 / 
thymocytes is reflected in its inability to upregulate CD5
expression in DPs, a marker of antigen receptor function.
The loss of CD5 upregulation is restored by expression of
active Rac-1 (11). The present data show that expression of
V14Rho does not restore CD5 expression to normal in
Vav-1 /  cells (Fig. 7 D). Vav-1 /  DPs ineffectively make
SP mature T lymphocytes because of defects in positive
and negative selection (10). Expression of active RhoA in
Vav-1 /  did not regenerate SP thymocytes.
Discussion
This study uses a T cell–specific promoter to express an
active Rho mutant, V14RhoA, in T cells of transgenic
mice. This allowed direct analysis of the consequences of
Rho activation for thymocyte development. Previously, it
has been shown that Rho function is necessary for the de-
velopment of pre-T cells; specifically for survival and pro-
liferative responses controlled by the pre-TCR and the
tyrosine kinase p56lck (12, 14, 19). RhoA was thus posi-
tioned downstream of the pre-TCR complex as part of the
signals this receptor used to determine pre-T cell fate. This
Figure 6. Differentiation of L61 Rac-1 pre-T cells is
dependent of RhoA function. (A) Thymocytes from L61
Rac-1, CD2-C3, and L61 Rac-1/CD2-C3 transgenic
mice were stained for CD4 and CD8, and analyzed by
flow cytometry. Dot plots show CD4/CD8 profiles. Re-
sults are representative of three independent experiments.
(B) Thymocytes from L61 Rac-1, CD2-C3, and L61
Rac-1/CD2-C3 transgenic mice were stained for CD25
and CD44, as described in Fig. 3 A, and analyzed by flow
cytometry. Dot plots show CD44/CD25 profiles in lin-
eage-null, Thy-1.2  cells. Results are representative of
three independent experiments.911 Corre et al.
study now shows that activation of RhoA is able to induce
integrin-mediated cell adhesion in thymocytes but is not
sufficient to allow pre-T cell survival, differentiation, or
proliferation in the absence of normal pre-TCR function.
The fact that RhoA is required but not sufficient for pre-T
cell differentiation means that RhoA must act in conjunc-
tion with other signaling molecules to determine the fate of
early T cell progenitors.
Previous work on Rho function in T cell biology has in-
evitably focused on pre-T cells because the effects of losing
Rho function in the thymi are so profound that very few
DP or SP T cells develop and those that do, transform to
form T cell lymphomas (33). The expression of V14RhoA
was not associated with any increased tendency of mice to
develop any malignancy (unpublished data). Moreover, the
failure of V14RhoA to modulate pre-T cell differentiation
means that it was possible to obtain DP and SP T cells ex-
pressing active RhoA in normal numbers and examine the
impact of RhoA signaling for the first time in more mature
T cell populations. One striking observation from these
studies of RhoA action was that this GTPase can potentiate
TCR- /  responses. The potency of RhoA as an amplifier
of TCR responses can be seen in vitro, the SP T cells that
differentiate in V14RhoA transgenic mice are hyperre-
sponsive to TCR responses in terms of proliferation despite
reduced TCR expression. Moreover, analysis of V14RhoA
mice in the context of expression of two defined TCR
transgenes revealed that RhoA activation strikingly aug-
mented positive selection consistent with enhanced TCR
responses in vivo.
The ability of RhoA to amplify responses mediated by
the TCR- /  complex was not seen in the context of pre-
TCR responses; these were unperturbed by RhoA activa-
tion. The pre-TCR comprises the TCR-  subunit paired
with the pre-T  subunit and the invariant CD3 chains (2).
The pre-TCR does not have a ligand, rather its assembly at
the plasma membrane in membrane microdomains is suffi-
cient to initiate signal transduction for pre-T cell develop-
ment (34–36). In DPs, the replacement of the pre-T  sub-
unit with the TCR-  chain generates the mature TCR- / 
which initiates signaling for selection when triggered by
antigen/MHC complexes present on the surface of thymic
epithelial cells. Cell–cell contacts mediated by integrins
have been suggested to provide a selective boost to signal-
Figure 7. Activated RhoA cannot rescue
thymocyte development in Vav-1 /  mice.
(A) Thymic cellularity in V14RhoA/Vav-
1 /  double transgenic mice. Thymocyte
cell numbers from 6–8-wk-old Vav-1 / 
(n   6), Vav-1 /  (n   5), and V14RhoA/
Vav-1 /  mice (n     5) are shown. (B)
CD25/CD44 profile in V14RhoA/Vav-
1 /  double transgenic mice. Thymocytes
from Vav-1 / , Vav-1 / , and V14RhoA/
Vav-1 /  mice were analyzed for expres-
sion of CD25 and CD44 as described pre-
viously. Dot plots for CD44/CD25 profiles
in lineage , Thy-1.2  cell are shown. (C) CD4/
CD8 profiles in V14RhoA/Vav-1 /  double
transgenic mice. Thymocytes from Vav-1 / ,
Vav-1 / , and V14RhoA/Vav-1 /  mice were
analyzed for expression of CD4 and CD8 as de-
scribed previously. Dot plots for CD4/CD8 pro-
files in Thy-1.2  cells are shown. (D) CD5 ex-
pression on CD4 CD8  DP thymocytes in
V14RhoA/Vav-1 /  double transgenic. Thy-
mocytes from Vav-1 / , Vav-1 / , and
V14RhoA/Vav-1 /  mice were analyzed for expression of CD4 and CD8 as described previously. CD5 expression was analyzed on CD4 CD8 
Thy1.2  cells. Results are representative of at least three independent experiments.912 In Vivo Analysis of RhoA Function
ing for positive selection of SPs in the thymus (28). This
study shows that RhoA activation is able to promote cell
adhesion in primary thymocyte populations. This would
facilitate and stabilize contacts between the T cell and cells
presenting antigen/MHC complexes and hence promote
SP differentiation. The pre-TCR would not be sensitive to
this RhoA-mediated phenomenon because it signals auton-
omously without the need for an exogenous ligand and
hence without dependency on cell contact.
Previous studies have shown that the GTPase Rac-1 can
drive significant pre-TCR differentiation in the absence of
the pre-TCR in Rag-1 /  mice and augment pre-TCR
responses in wild-type mice (11). Herein we show that
Rho signaling is not sufficient to allow pre-T cell survival,
differentiation, or proliferation in the absence of normal
pre-TCR function, nor could V14RhoA mimic active
Rac-1 and amplify pre-TCR signals. Nevertheless, Rac-1
actions in pre-T cells require Rho function. The actions of
Rac-1 in pre-T cell differentiation thus involve RhoA but
must require additional effectors. We have also noted that
developmental defects caused by loss of the GEF Vav-1 in
pre-T cells can be corrected by expression of activated
Rac-1 that modulates actin dynamics (11). The effects of
Rac-1 on actin structures are best studied in fibroblasts
where it is noted that Rac-1 activation induces lammelipo-
dia formation and then goes on to trigger RhoA-mediated
actin metabolism that culminates in the formation of focal
adhesion complexes (31, 32). In this respect, in transformed
cell lines Rho and Rac have been reported to have a simi-
lar impact on the lymphocyte cytoskeleton (20). However,
this report shows that only activation of Rac-1 can com-
pensate for loss of Vav-1 in pre-T cells whereas activation
of RhoA cannot. Rac-1 and RhoA thus do not have inter-
changeable functions in the thymus and there must be
unique actions of Rac-1 on the cytoskeleton relevant to
pre-T cell biology that cannot be triggered by RhoA.
In summary, this study extends our understanding of
the importance of RhoA in the thymus and reveals that,
besides its involvement in early thymocyte development,
this GTPase also regulates cell adhesion in thymocytes and
regulates thymocyte positive selection. This study also re-
veals Rho signaling is necessary but not sufficient to allow
pre-T cell survival, differentiation, or proliferation in the
absence of normal pre-TCR function. Finally, this study
reveals signaling crosstalk between the GTPases Rac-1 and
RhoA in the thymus. Rac-1–induced pre-T cell differen-
tiation required Rho function but is not mediated solely
by RhoA. It remains to be determined if Rac-1 and
RhoA operate in linear or parallel pathways to control
thymocyte development.
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